Ferring Pharmaceuticals AS’s heat-stable formulation of carbocetin was authorized in Switzerland using the new Marketing Authorization for Global Health Products (MAGHP) procedure. It will now undergo rapid assessments in seven participating African countries, based on the Swiss approval dossier.
The new formulation, which was added to the World Health Organization’s Essential Medicines List (EML) last year, was developed by Ferring to address problems with refrigeration and cold-chain transport of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?